공고 • Jul 16
Regen BioPharma Inc Settles Lawsuit With Trillium Partners LP Regen BioPharma Inc. reported that on April 13, 2026 a complaint was filed against the Company in the Superior Court of California, County of San Diego . Trillium Partners, LP,(the “ Plaintiff”), who has acquired rights to $398,740 of claims against the Company, sought damages in that amount along with attorneys’ fees and costs. On May 14, 2026 the Company and the Plaintiff entered into a Settlement and Mutual Release Agreement (“Agreement”). Pursuant to the terms and conditions of the Agreement following the entry of an Order by the Court after a fairness hearing pursuant to Section 3(a) (10) of the Securities Act of 1933 (the “Securities Act”), and Section 25142 of the California Corporations Code (the “Corporations Code”) and the delivery by the Plaintiff and the Company of the Stipulation of Dismissal in settlement of the Claims, the Company shall issue and deliver to the Plaintiff shares of its Common Stock or Series A Preferred Stock (the “Settlement Shares”) in one or more tranches as necessary, and subject to adjustment and ownership limitations as set forth in the Agreement, sufficient to generate proceeds such that the aggregate Remittance Amount equals the Claim Amount. The Remittance Amount shall mean sixty five percent (65%) of Net Proceeds of the sale of Settlement Shares. On July 10, 2026, after a Fairness Hearing, the Superior Court of California issued an order approving issuance of the Settlement Shares pursuant to Section 3(a) (10) of the Act and Section 25142 of the Corporations Code . 공고 • Nov 17
Regen BioPharma, Inc. has filed a Follow-on Equity Offering in the amount of $1 million. Regen BioPharma, Inc. has filed a Follow-on Equity Offering in the amount of $1 million.
Security Name: Common Stock
Security Type: Common Stock
Securities Offered: 100,000,000
Price\Range: $0.01 공고 • Sep 24
Regen Biopharma, Inc. Announces Update on Its Application for Orphan Drug Status to the U.S. Food and Drug Administration for Hemaxellerate Regen BioPharma, Inc. announced the Company will be presenting an update on its application for Orphan Drug status to the U.S. Food and Drug Administration (FDA) for HemaXellerate. This therapy is anticipated being used in treating plastic anemia. Additionally the Company anticipates HemaXellerate may be used in addressing the side effects of Chemotherapy, a market of several billions of dollars. 공고 • Sep 05
Regen BioPharma, Inc. Explores Expanded Use of HemaXellerate for Chemotherapy-Induced Bone Marrow Suppression Regen BioPharma, Inc. announced its ongoing efforts to expand the clinical development of HemaXellerate, its novel cellular therapy, to address chemotherapy-induced bone marrow suppression, a serious and common complication in cancer patients undergoing cytotoxic treatments. This represents potentially a market in excess of $1 billion per year in just the US. Following the recent submission of an Orphan Drug Application for the treatment of aplastic anemia, Regen BioPharma is broadening its focus to include non-orphan indications where HemaXellerate may offer a transformative approach to unmet medical needs in oncology supportive care. Current standard-of-care treatments include: Colony-Stimulating Factors (e.g., G-CSF, GM-CSF): Promote white blood cell production but have limited effects on red cells or platelets. Erythropoiesis-Stimulating Agents (ESAs): Used for anemia but carry cardiovascular and thrombotic risks. Platelet transfusions: Temporary and often limited by availability and patient tolerance. These therapies are largely single-lineage, symptomatic, and reactive. They do not address the root cause: damaged or suppressed hematopoietic stem cell function. HemaXellerate: A Multi-Lineage Regenerative Approach: In contrast, HemaXellerate is designed to stimulate the body's own hematopoieticstem cells, enhancing the recovery of all three major blood cell lines--erythrocytes, leukocytes, and platelets--simultaneously. Unlike traditional treatments that target specific symptoms or lineages, HemaXellerate acts upstream by restoring bone marrow microenvironment function and promoting endogenous hematopoiesis. The stem cell literature indicates that HemaXellerate will: Accelerate bone marrow recovery following cytotoxic injury; Enhance resilience to repeated chemotherapy cycles; Reduce dependence on transfusions and secondary supportive drugs. 공고 • Aug 30
Regen BioPharma, Inc. has filed a Follow-on Equity Offering in the amount of $5 million. Regen BioPharma, Inc. has filed a Follow-on Equity Offering in the amount of $5 million.
Security Name: Common Stock
Security Type: Common Stock
Securities Offered: 25,000,000
Price\Range: $0.1 to $0.2 공고 • Aug 15
Regen BioPharma, Inc. Provides Further Insight into Its Planned Phase 1 Clinical Trial of HemaXellerate Regen BioPharma, Inc. provided further insight into its planned Phase 1 clinical trial of HemaXellerate, the company's innovative stem cell-derived therapy, which has already received U.S. FDA clearance. While the initial focus is on treating aplastic anemia, a rare orphan indication, Regen BioPharma is evaluating expanded applications for this therapy in markets poised for significant growth. Regen sees substantial potential in treating chemotherapy-induced bone marrow suppression, a market projected to be valued at well in excess of $1 billion annually. HemaXellerate is designed to stimulate bone marrow transplantation following injury caused by autoimmune conditions, chemotherapy, or radiation. HemaXellerate are comprised of cells extracted from the patient's own fat tissue and processed using a proprietary method to induce a biological response in the patient that heal damaged bone marrow and improves the body's ability to generate healthy blood cells. To ensure the trial's success, Regen BioPharma has partnered with a clinical research organization (CRO) known for its expertise in conducting complex trials. Once initiated, the study is expected to reach completion within 12 to 14 months. Opportunity: Aplastic anemia is a rare disease with high unmet medical need, offering the potential for accelerated regulatory pathways and market exclusivity. Massive Market Potential: Expansion into chemotherapy-induced bone marrow suppression could unlock a multi-billion-dollar market. Strategic Execution: Collaboration with a leading CRO ensures focused execution and timeline adherence. 
